论文部分内容阅读
β受体阻滞剂继血管紧张素转换酶抑制剂(ACEI)之后,成为新的改善心衰患者预后和降低病死率的药物。然而由于认识有误,我国适合用β受体阻滞剂的心衰患者,只有1/3正在使用该药,多数未能接受β受体阻滞剂治疗。
Beta blockers, following angiotensin converting enzyme inhibitors (ACEIs), have become the new drug to improve the prognosis and reduce the mortality in patients with heart failure. However, due to misunderstanding, our country suitable for β-blockers in patients with heart failure, only 1/3 are using the drug, the majority failed to accept β-blocker therapy.